Skip to main content
Skip to "About this site"

Table A.15.1

Warning View the most recent version.

Archived Content

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please "contact us" to request a format other than those available.

Table A.15.1
Total in-house research and development (R&D) expenditures by bioproducts establishments in Canada, by region, 2014 and 2015
Table summary
This table displays the results of Total in-house research and development (R&D) expenditures by bioproducts establishments in Canada. The information is grouped by Region (appearing as row headers), 2014 and 2015, calculated using $ thousands units of measure (appearing as column headers).
Region	2014	2015
Region	$ thousands
Canada
Total In-house R&D expenditures	121,611^{Table A.15.1 Note D}	112,132^{Table A.15.1 Note D}
Current in-house R&D expenditures	90,195^{Table A.15.1 Note D}	86,604^{Table A.15.1 Note D}
Capital in-house R&D expenditures	31,415^{Note E: Use with caution}	25,528^{Note E: Use with caution}
Atlantic provinces
Total In-house R&D expenditures	2,883^{Note E: Use with caution}	1,460^{Note E: Use with caution}
Current in-house R&D expenditures	289^{Note E: Use with caution}	433^{Note E: Use with caution}
Capital in-house R&D expenditures	2,594^{Note E: Use with caution}	1,027^{Note E: Use with caution}
Quebec
Total In-house R&D expenditures	26,401^{Table A.15.1 Note D}	29,648^{Table A.15.1 Note D}
Current in-house R&D expenditures	18,080^{Table A.15.1 Note D}	17,999^{Table A.15.1 Note D}
Capital in-house R&D expenditures	8,321^{Note E: Use with caution}	11,649^{Note E: Use with caution}
Ontario
Total In-house R&D expenditures	61,293^{Note E: Use with caution}	60,113^{Note E: Use with caution}
Current in-house R&D expenditures	55,761^{Note E: Use with caution}	51,652^{Note E: Use with caution}
Capital in-house R&D expenditures	5,532^{Note E: Use with caution}	8,461^{Note E: Use with caution}
Prairies
Total In-house R&D expenditures	3,910^{Note E: Use with caution}	5,557^{Note E: Use with caution}
Current in-house R&D expenditures	3,667^{Note E: Use with caution}	4,976^{Note E: Use with caution}
Capital in-house R&D expenditures	243^{Note E: Use with caution}	581^{Note E: Use with caution}
British Columbia
Total In-house R&D expenditures	27,123^{Note E: Use with caution}	15,355^{Note E: Use with caution}
Current in-house R&D expenditures	12,398^{Note E: Use with caution}	11,546^{Note E: Use with caution}
Capital in-house R&D expenditures	14,725^{Note E: Use with caution}	3,810^{Note E: Use with caution}
^E use with caution Note: Coefficient of variation (CV) threshold Note D [ 0.150 < CV ≤ 0.250 ] Return to note D referrer Preliminary estimates, subject to change. Due to rounding, components may not add to totals. Coefficient of variation (CV) and standard error (SE) are used as quality indicators. Source: Statistics Canada, Bioproducts production and development survey 2015.

Date modified:: 2017-12-22